Clinically Important Drug Interactions with Anticoagulants: An Update

Clinical Pharmacokinetics

Volumn 30, Issue 6, 1996, Pages 416-444

  Harder, Sebastian ^a   Thürmann, Petra ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ARYLPROPIONIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PHENYLACETIC ACID DERIVATIVE; PHENYLBUTAZONE; PROTON PUMP INHIBITOR; QUINOLONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW;

ANTICOAGULANTS; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0029886356     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630060-00002     Document Type: Review

References (224)

1. Koch-Weser J. Hemorrhagic reactions and drug interactions in 500 warfarin-treated patients. Clin Pharmacol Ther 1973; 14 (1): 139
2. Jankel CA, McMillan JA, Martin BC. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm 1994 Mar 1; 51: 661-6
3. Koch-Weser J. Drug interactions in cardiovascular therapy. Am Heart J 1975 Jul; 90 (1): 93-116
4. Freedman MD, Olatidoye AG. Clinical significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10 (5): 381-94
5. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994 Nov 1; 121 (9): 676-83
6. Kuhlmann J. Drug interaction studies during drug development: which, when, how? Int J Clin Pharmacol Ther 1994; 32: 305-11
7. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504
8. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet 1989; 16: 238-53
9. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994 Sep; 56 (3): 286-94
10. Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37: 563-9
11. Bentley DP, Backhouse G, Hutchings A, et al. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22: 37-41
12. Mungall DR, Ludden TM, Marshall J, et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13 (3): 213-27
13. Toon S, Heimark LD, Trager WF, et al. Metabolic fate of phenprocoumon in humans. J Pharm Sci 1985 Oct; 74 (10): 1037-40
14. Chriske HW, Gross R, Hilger HH, et al. Pharmakokinetische Untersuchungen zur Phenprocoumon (Marcumar)-Resistenz. Verh Dtsch Ges Inn Med 1973; 79: 1311-4
15. Husted S, Andreasen F. Individual variation in the response to phenprocoumon. Eur J Clin Pharmacol 1977; 11: 351-8
16. Trenk D, Althen H, Jähnchen E, et al. Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol 1987; 33: 49-54
17. Jähnchen E, Meinertz T, Gilfrich H-J, et al. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 1976; 20 (3): 342-9
18. Dieterle W, Faigle JW, Montigel C, et al. Biotransformation and pharmacokinetics of acenocoumarol (Sintrom®) in man. Eur J Clin Pharmacol 1977; 11: 367-75
19. Thijssen HHW, Baars LG. Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? Br J Clin Pharmacol 1983; 16: 491-6
20. Godbillon J, Richard J, Gerardin A, et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981; 12: 621-9
21. Popovic J, Mikov M, Jakovljevic V. Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. Eur J Drug Metab Pharmacokinet 1994; 19 (2): 85-9
22. Meinertz T, Kasper W, Kahl C, et al. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 1978; 5: 187-8
23. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995 Jul 6; 333 (1): 11-17
24. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995 Jul 6; 333 (1): 5-10
25. Fihn SD. Aiming for safe anticoagulation. N Engl J Med 1995 Jul 6; 333 (1): 54-5
26. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-8
27. Toon S, Hopkins KJ, Garstang FM, et al. The warfarin-cimetidine interaction: stereochemical considerations. Br J Clin Pharmacol 1986; 21: 245-6
28. Bell WR, Anderson KC, Noe DA, et al. Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med 1986 Dec; 146: 2325-8
29. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol 1984; 17: 559-64
30. Bax NDS, Lennard MS, Tucker GT, et al. The effect of β-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. Br J Clin Pharmacol 1984; 17: 553-7
31. Spahn H, Kirch W, Mutschler E, et al. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br J Clin Pharmacol 1984; 17 Suppl. 1: 97S-102S
32. Harder S, Brei R, Caspary S, et al. Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. Eur J Clin Pharmacol 1993; 44: 583-6
33. Vinazzer H. Effect of the beta-blocking agent Visken on the action of coumarin. Int J Clin Pharmacol Biopharm 1975; 12: 458-60
34. Gazzaninga AB, Stewart DR. Possible quinidine induced hemorrhage in a patient on warfarin sodium. N Engl J Med 1969; 280: 711
35. Sylvén C, Anderson P. Evidence that disopyramide does not interact with warfarin [letter]. BMJ 1983 Apr 9; 286: 1181
36. Trenk D, Möhrke W, Warth L, et al. Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. Arzneimittelforschung 1993; 43 (8): 836-41
37. Martinowitz U, Rabinowici J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981 Mar 12; 304 (11): 671-2
38. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988 Aug; 148: 1779-81
39. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose - and concentration - dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985; 28: 257-61
40. O'Reilly RA, Trager WF, Rettie AE, et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987 Sep; 42 (3): 290-4
41. Caraco Y, Chajek-Shaul T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. Thromb Haemost 1989; 62 (3): 906-8
42. Fondevila C, Meschengieser S, Lazzari MA. Amiodarone potentiates acenocoumarin. Thromb Res 1989; 53 (2): 203-8
43. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol 1985; 28: 625-9
44. Kates RE, Yee Y-G, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987 Sep; 42 (3): 305-11
45. Körst HA, Brandes J-W, Littmann K-P. Cave: Propafenon potenziert Wirkung von oralen Antikoagulantien. Med Klin 1981; 76 (12): 349-50
46. Benedek IH, King S-YP, Powell RJ, et al. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Clin Pharmacol 1992; 32: 558-63
47. Van Hecken A, De Lepeleire I, Verbesselt R, et al. Effect of benazepril, a converting enzyme inhibitor, on plasma levels and activity of acenocoumarol and warfarin. Int J Clin Pharmacol Res 1988; 8 (5): 315-19
48. Van Hecken A, Verhesselt R, Depré M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993; 45: 291-3
49. Boeijinga JK, Breimer DD, Kraay CJ, et al. Absence of interaction between the ACE inhibitor cilazapril and coumarin derivatives in elderly patients on long term oral anticoagulants. Proceedings of the British Pharmacological Society Meeting; 1991 Dec 17-19: London. Br J Clin Pharmacol 1992 May; 33 (5): 553P
50. Boeijinga JK, Matroos AW, van Maarschalkerweerd MW, et al. No interaction shown between ramipril and coumarine derivatives. Curr Ther Res 1988 Dec; 44 (6): 902-8
51. Verho M, Malerczyk V, Grötsch H, et al. Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent. Pharmatherapeutics 1989; 5 (6): 392-9
52. O'Reilly RA. Spironolactone and warfarin interaction. Clin Pharmacol Ther 1980 Feb; 27 (2): 198-201
53. O'Reilly RA, Sahud MA, Aggeler PM. Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man. Ann NY Acad Sci 1971; 179: 173-86
54. Robinson DS, Sylwester D. Interaction of commonly prescribed drugs and warfarin. Ann Intern Med 1970 Jun; 72 (6): 853-6
55. Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther 1970; 11 (4): 524-9
56. Petrick RJ, Kronacher N, Alcena V. Interaction between warfarin and ethacrynic acid. JAMA 1975 Feb 24; 231 (8): 843-4
57. Donaldson DR, Sreeharan N, Crow MJ, et al. Assessment of the interaction of warfarin with aspirin and dipyridamole [letter]. Thromb Haemost 1982; 47 (1): 77
58. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983 May 15; 51: 1537-41
59. Fagan SC. Safety of combination aspirin and anticoagulation in acute ischemic stroke. Ann Pharmacother 1994; 28: 441-3
60. O'Reilly RA. Phenylbutazon and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. Arch Intern Med 1982 Sep; 142: 1634-7
61. Miners JO, Foenander T, Wanwimolruk S, et al. Interaction of sulphinpyrazone with warfarin. Eur J Clin Pharmacol 1982; 22: 327-31
62. Heimark LD, Toon S, Gibaldi M, et al. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans. Clin Pharmacol Ther 1987 Sep; 42 (3): 312-19
63. Stoysich AM, Lucas BD, Mohiuddin SM, et al. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther 1996; 34: 56-60
64. Jähnchen E, Meinertz T, Gilfrich H-J, et al. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978; 5: 437-40
65. Robinson DS, Benjamin DM, McCormick JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacocol Ther 1971; 12: 491-5
66. Meinertz T, Gilfrich H-J, Groth U, et al. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther 1977; 21 (6): 731-5
67. Harvengt C, Desager JP. Effect of colestipol, a new bile acid sequestrant, on the absorption of phenprocoumon in man. Eur J Clin Pharmacol 1973; 6 (1): 19-21
68. Hunninghake DB, Pollack E. Effect of bile acid sequestering agents on the absorption of aspirine, tolbutamide and warfarin. Fed Proc 1977; 36: 996
69. Bjornsson TD, Meffin PJ, Blaschke TF. Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin. J Pharmacokinet Biopharm 1977; 5 (5): 495-505
70. Bjornsson TD, Meffin PJ, Swezey SE, et al. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. J Pharmacol Exp Ther 1979; 210: 322-6
71. Zimmermann SW, Moorthy AV, Dreher WH, et al. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 1983; 75: 920-7
72. Ahmad S, Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990 Oct; 98 (4): 1041-2
73. Verstreate M, Boogaerts MA. Haematological disorders. In: Speight TM, editor. Avery's drug treatment. 3rd ed. Auckland: Adis Press, 1987: 958-1022
74. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992 Oct 17; 340: 979-80
75. Keech A, Collins R, McMahon S, et al. Oxford Cholesterol Study Group: three year follow up of the Oxford Cholesterol Study. Eur Heart J 1994; 15: 255-68
76. Ahmad S, Lovastatin. Warfarin interaction. Arch Intern Med 1990 Nov; 150 (11): 2407
77. Jassal SV. Warfarin potentiated by proguanil. BMJ 1991 Sep 28; 303: 789
78. Heine P, Kewitz H, Wiegboldt K-A. The influence of hypoglycaemic sulphonylureas on elimination and efficacy of phenprocoumon following a single oral dose in diabetic patients. Eur J Clin Pharmacol 1976; 10: 31-3
79. Ohnhaus EE, Berger W, Duckert F, et al. The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. Klin Wochenschr 1983; 61: 851-8
80. Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet 1979 Aug 18; 11 (8138): 317-19
81. Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med 1990 Jan 1; 112 (1): 76-7
82. Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin after ranitidine and cimetidine. Clin Pharmacol Ther 1984 Mar; 35 (3): 338-41
83. O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984 May; 144: 989-91
84. Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987; 32: 165-72
85. Harenberg J, Zimmermann R, Staiger C, et al. Lack of effect of cimetidine on action of phenprocoumon. Eur J Clin Pharmacol 1982; 23: 365-7
86. De Lepeleire I, Van Hecken A, Verbesselt R et al. Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res 1990; 10: 167-71
87. Unge P, Svedberg L-E, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509-12
88. Duursema L, Müller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700-3
89. Mungall D, Talbert RL, Phillips C, et al. Sucralfate and warfarin [letter]. Ann Intern Med 1983; 98: 557
90. Neuvonen PJ, Jaakkola A, Tötterman J, et al. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol 1985; 20: 178-80
91. Ambre JJ, Fischer LJ. Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man. Clin Pharmacol Ther 1973; 14 (2): 231-7
92. Aggeler PM, O'Reilly RA, Leong L, et al. Potentiation of anticoagulant effect of warfarine by phenylbutazone. N Engl J Med 1976; 276: 496-501
93. Savitsky JP. Fenbufen-warfarin interaction in healthy volunteers. Clin Pharmacol Ther 1980 Feb; 27 (2): 284
94. Vesell ES, Passananti T, Johnson AO. Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol 1975; 15: 486-95
95. Chan TYK, Lui SF, Chung SY, et al. Adverse interaction between warfarin and indomethacin. Drug Saf 1994; 10 (3): 267-9
96. Michot F, Ajdacic K, Glaus L. A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (Nicoumalone). J Int Med Res 1975; 3: 153-7
97. Toon S, Holt BL, Mullins FGP, et al. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990; 30: 743-750
98. Loftin I, Vesell ES. Interaction between sulindac and warfarin: different results in normal subjects and in an unuasual patient with a potassium-losing renal tubular defect. J Clin Pharmacol 1979; 19: 733-42
99. Ross JRY, Beeley L. Sulindac. Prothrombin time and anticoagulants [letter]. Lancet 1979; II (1075)
100. Carter SA. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants [letter]. Lancet 1979 Sep 29; II: 698-9
101. Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Curr Ther Res 1975; 18: 862
102. Jacono A, Caso P, Gualtieri S, et al. Clinical study of possible interactions between indoprofen and oral anticoagulants. Eur J Rheumatol Inflamm 1981; 4: 32-5
103. Flessner MF, Knight H. Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen [letter]. JAMA 1988 Jan 15; 259 (3): 353
104. Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol 1993; 44: 205-6
105. Jain A, McMahon FG, Slattery JT, et al. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979 Jan; 25 (1): 61-6
106. Slattery JT, Levy G, Jain A, et al. Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin. Clin Pharmacol Ther 1979 Jan; 25 (1): 51-60
107. Marbel GA, Duckert F, Walter M, et al. Interaction study between phenprocoumon and flurbiprofen. Curr Med Res Opin 1977; 5 (1); 26-31
108. Stricker BHC, Delhez JL. Interactions between flurbiprofen and coumarins [letter]. BMJ 1982 Sep 18; 285: 812-13
109. Dürr J, Pfeiffer MH, Penth B, et al. Untersuchung zur Frage einer Interaktion von Tiaprofensäure und Phenprocoumon. Arzneimittelforschung 1981; 31 II (12): 2163-7
110. Meurice J. Interaction of tiaprofenic acid and acenocoumarol. Rheumatology 1982; 7: 111-17
111. Rhodes RS, Rhodes PJ, Klein C et al. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985; 91: 556-8
112. Dahl SL, Ward JR. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy 1982 Mar-Apr; 2 (2): 80-9
113. Farnham DJ. Studies of isoxicam in combination with aspirin, warfarin sodium and cimetidine. Semin Arthritis Rheum 1982; 12 Suppl. 2: 179-83
114. Eichler HG, Jung M, Kyrle PA, et al. Absence of interaction between tenoxicam and warfarin. Eur J Clin Pharmacol 1992; 42 (2): 227-9
115. Perucca E. Drug interactions with nimesulide. Drugs 1993; 46 Suppl. 1: 79-82
116. Harder S, Thürmann P, Hermann R, et al. Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. Int J Clin Pharmacol Ther 1994; 32 (11): 577-81
117. Boeijinga JJ, Boerstra EE, Ris P, et al. Interaction between paracetamol and coumarin anticoagulants. Lancet 1982 Feb 27; 1: 506
118. O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975 Oct; 83 (4): 506-8
119. Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987 Oct; 42 (4): 388-94
120. Boekhout-Mussert RJ, Bieger R, van Brummelen P, et al. Inhibition by rifampicin of the anticoagulant effect of phenprocoumon. JAMA 1974 Sep 30; 229 (14): 1903-4
121. Rosenthal AR, Self TH, Baker ED, et al. Interaction of isoniazid and warfarin. JAMA 1977 Nov 14; 238 (20): 2177
122. Bianco TM, Bussey HI, Farnett LE, et al. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 1992; 12 (6): 435-9
123. Rindone JP, Kelley CL, Jones WN, et al. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin Pharm 1991 Feb; 10: 136-8
124. Rocci ML, Vlasses PH, Distlerath LM, et al. Norfloxacin does not alter warfarin's disposition or anticoagulant effect. J Clin Pharmacol 1990; 30: 728-32
125. Millar E, Coles S, Wyld P, et al. Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects. Clin Pharmacokinet 1992; 22 Suppl. 1: 102-6
126. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions. Am J Med 1993 Mar 22; 94 Suppl. 3A: 56S-69S
127. Verho M, Malerczyk V, Rosenkranz B, et al. Absence of interaction between ofloxacin and phenprocoumon. Curr Med Res Opin 1987: 10 (7): 474-9
128. Toon S, Hopkins KJ, Garstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987 Jul; 42 (1): 33-41
129. Jolson HM, Tanner LA, Green L, et al. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991 May; 151: 1003-4
130. Linville T, Matanin D. Norfloxacin and warfarin [letter]. Ann Intern Med 1989 May 1; 100 (5): 751-2
131. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin [letter]. Ann Intern Med 1989 Sep 15; 111 (6): 542-3
132. Linville D, Emory C, Graves L. Ciprofloxacin and warfarin interaction. Am J Med 1991 Jun; 90: 765
133. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin. Ann Intern Med 1993 Dec 15; 119 (12): 1223
134. Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin [leller]. Ann Intern Med 1987; 107: 601
135. Hoffbrand BI. Interaction of nalidixic acid and warfarin [letter]. BMJ 1974 Jun 22; 2: 666
136. Bachmann K, Schwartz, JI, Forney R, et al. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984; 28: 171-6
137. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984 Dec; 144: 2413-4
138. Hassell D, Utt JK. Suspected interacton: warfarin and erythromycin. South Med J 1985; 78: 1015-6
139. Grau E, Fontcuberta J, Félez J. Erythromycin: oral anticoagulants interaction [letter]. Arch Intern Med 1986 Aug; 146: 1639
140. Paulsen O, Nilsson L-G. Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988; 63: 215-20
141. Davis RL, Berman W, Wernly JA, et al. Warfarin-nafcillin interaction. J Pediatr 1991 Feb; 118 (2): 300-3
142. Taylor AT, Pritchard DC, Goldstein AO, et al. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994 Aug; 39 (2): 182-5
143. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Ann Surg 1987 Aug; 206 (2): 155-61
144. Parker SW, Baxter J, Beam TR. Cefoperazone-induced coagulopathy. Lancet 1984 May 5; 1: 1016
145. Cristiano P. Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm 1984 Apr; 18: 314-16
146. Solo J, Sacristan JA, Alsar MJ, et al. Probable acenocoumarolamoxycillin interaction. Acta Haematol 1993; 90: 195-7
147. Cullen SI, Catalano PM. Griseofulvin-warfarin antagonism. JAMA 1967 Feb 20; 199 (8): 582-3
148. Kazmier FJ. A significant interaction between metronidazole and warfarin. Mayo Clin Proc 1976 Dec; 51: 782-4
149. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976 Aug 12; 295 (7): 354-7
150. Colquhoun MC, Daly M, Stewart P, et al. Interaction between warfarin and miconazole oral gel. Lancet 1987 Mar 21; 1: 695-6
151. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992 Jun; 51 (6): 656-67
152. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993 Sep-Oct; 13 (5): 508-9
153. Yeh J, Soo S-C, Summerton C, et al. Potentiation of action of warfarin by itraconazole [letter]. BMJ 1990 Sep 29; 301: 669
154. Smith AG. Potentiation of oral anticoagulants by ketoconazole. BMJ 1984 Jan 21; 288: 188-9
155. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet 1969 Dec 27; 11: 1397-9
156. Yacobi A, Lai C-M, Levy G. Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and chloramphenicol in rats. J Pharmacol Exp Ther 1984; 231 (1): 80-4
157. Hassall C, Feelam CL, Leach RH, et al. Potentiation of warfarin by co-trimoxazole [letter]. Lancet 1975 Dec 6; 11: 1155-56
158. O'Reilly RA. Stereoselective interaction of trimethoprimsulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980 Jan 3; 302 (1): 33-5
159. Lodwick R, MeConkey B, Brown AM, Life threatening interaction between tamoxifen and warfarin. BMJ 1987 Oct 31; 295: 1141
160. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989 Jan 14; 298: 93
161. Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. Am J Med 1992 Feb; 92: 217
162. Rivier G, Khamashta MA, Hughes GRV. Warfarin and azathioprine: a drug interaction does exist [letter]. Am J Med 1993 Sep; 95: 342
163. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994 Apr: 28 (4): 464-7
164. Chlebowski RT, Gota CH, Chan KK, et al. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 1982; 42: 4827-30
165. Burning PF, Bonfrèr JGM. Aminoglutethimide and oral anticoagulant therapy [letter]. Lancet 1983 Sep 3; 11: 582
166. Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemother Pharmacol 1984; 12: 10-12
167. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/mesna and pertubation of warfarin anticoagulant control. Postgrad Med J 1990; 66: 860-1
168. O'Reilly RA, Trager WF, Motley CH, et al. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980 (Aug); 28 (2): 187-95
169. MacDonald MG, Robinson DS, Sylwester D, et al. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responses in man. Clin Pharmacol Ther 1969; 10 (1): 80-4
170. Udall JA. Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 1975 Jan; 35: 67-71
171. Antlitz AM, Tolentino M, Kosai MF. Effect of butabarbital on orally administered anticoagulants. Curr Ther Res 1968 Feb; 10 (2): 70-3
172. Kopera H, Schenk H, Stulemeijer S. Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma g-GT in patients receiving mianserin. Eur J Clin Pharmacol 1978; 13: 351-6
173. Pond SM, Graham GG, Birkett DJ, et al. Effects of tricyclic antidepressants on drug metabolism. Clin Pharmacol Ther 1975; 18 (2): 191-9
174. Vesell ES, Passananti GT, Greene FE. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med 1970 Dec 31; 283 (27): 1484-8
175. Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. BMJ 1980 Jun 14; 280: 1415-6
176. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990 Aug; 83 (8): 981
177. Hansen JM, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12 (3): 539-43
178. Krämer G, Tettenborn B, Klosterskov-Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992 Nov; 33 (6): 1145-8
179. Nappi JM, Warfarin and phenytoin interaction [letter]. Ann Intern Med 1979 May; 90 (5): 852
180. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm 1984 Mar/Apr; 3: 200-3
181. Panegyres PK, Rischbieth RH. Fatal phenytoin warfarin interaction [letter]. Postgrad Med J 1991; 67: 98
182. O'Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther 1981 Mar; 29 (3): 332-6
183. Mönig H, Baese C, Heidemann HT, et al. Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. Br J Clin Pharmacol 1990; 30: 115-18
184. De Teresa E, Vera A, Ortigosa J, et al. Interaction between anticoagulants and contraceptives: an unsuspected finding. BMJ 1979 Nov 17; 2: 1260-1
185. Meeks ML, Mahaffey KW, Katz MD. Danazol increases the anticoagulant effect of warfarin. Ann Pharmacother 1992 May; 26: 641-2
186. Husted S, Andreasen F, Foged L. Increased sensivity to phenprocoumon during methyltestosterone therapy. Eur J Clin Pharmacol 1976; 10: 209-16
187. Schrogie JJ, Solomon HM. The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clin Pharmacol Ther 1967; 8 (1 Pt 1): 70-7
188. Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect by L-thyroxine. Clin Pediatr 1984 Mar; 23 (3): 172-4
189. Rice AJ, McIntosh TJ, Fouts JR, et al. Decreased sensitivity to warfarin in patients with myxedema. Am J Med Sci 1971 Oct; 262 (4): 211-15
190. Self TH, Evans WE, Ferguson T. Drug enhancement of warfarin activity [letter]. Lancet 1975 Sep 20; 11: 557-8
191. Jähnchen E, Meinertz T, Gilfrich HJ. Interaction of allopurinol with phenprocoumon in man. Klin Wochenschr 1977; 55: 759-61
192. Pan HYM, Ng RP. The effect of nootropil in a patient on warfarin [letter]. Eur J Clin Pharmacol 1983; 24: 711
193. Ingerslev J, Mouritzen C, Stenbjerg S. Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study. Pharmatherapeutica 1986; 4 (9): 595-600
194. Skovsted L, Kristensen M, Hansen JM, et al. The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism. Acta Med Scand 1976; 199: 513-5
195. Kristensen M, Hansen JM. Accumulation of chlorpropamide caused by dicoumarol. Acta Med Scand 1968; 183: 83-6
196. Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128-32
197. Williams JRB, Griffin JP, Parkins A. Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. Q J Med 1976 (XLV): 63-73
198. Lo ACT, Chan K, Young JHK, et al. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet 1992; 17 (4): 257-62
199. Rosenthal G. Interaction of ascorbic acid and warfarin [letter]. JAMA 1971 Mar 8; 215 (10): 1671
200. Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet 1994 Nov 12; 344: 1372-3
201. Steinijans VW, Hartmann M, Huber R et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1992; 30 Suppl. 1: S63-S67
202. Physcians Desk Reference. Montvale: Medical Economics Production Co., 1995
203. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204-20
204. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22 (5): 359-74
205. Hirsh J. Heparin. N Engl J Med 1991 May 30; 324 (22): 1565-74
206. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991 Feb; 151: 333-7
207. Col J, Col-Debeys C, Lavenne-Pardonge E, et al. Propylene glycol-induced heparin resistance during nitroglycerin infusion. Am Heart J 1985; 110 (1 Pt 1): 171-3
208. Habbab MA, Haft JI. Intravenous nitroglycerin and heparin resistance [letter]. Ann Intern Med 1986; 105: 305
209. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. Arch Intern Med 1987 May; 147: 857-60
210. Bode V, Welzel D, Franz G, et al. Absence of drug interaction between heparin and nitroglycerin. Randomized placebo-controlled crossover study. Arch Intern Med 1990 Oct; 150: 2117-9
211. Lepor NE, Amin DK, Berberian L, et al. Does nitroglycerin induce heparin resistance? Clin Cardiol 1989 Aug; 12: 432-4
212. Berk SI, Grunwald A, Pal S, et al. Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. Am J Cardiol 1993 Aug 15; 72: 393-6
213. Becker RC, Corrao JM, Bovill EG, et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990 Jun; 119 (6): 1254-61
214. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980 Sep 12; 244 (11): 1209-12
215. Heiden D, Rodvien R, Mielke CH. Heparin bleeding, platelet dysfunction, and aspirin [letter]. JAMA 1981 Jul 24/31; 246 (4): 330-1
216. Zahger D, Maaravi Y, Matzner Y, et al. Partial resistance to anticoagulation after streptokinase treatment for acute myocardial infarct. Am J Cardiol 1990 Jul 1; 66: 28-30
217. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 1989; 29: 1043-7
218. Desmond PV, Roberts RK, Wood AJJ, et al. Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol 1980; 9: 171-5
219. Storstein L, Janssen H. Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 1976; 20: 15-23
220. Lohman JJHM, Hooymans PM, Koten MLP, et al. Effect of heparin on digitoxin protein binding. Clin Pharmacol Ther 1985; 37: 55-60
221. De Smet AAEA, Joen MCN, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990; 100: 520-7
222. Levy JH, Salmenpera MT. Increased anticoagulation during cardiopulmonary bypass by aprotinin [letter]. J Thorac Cardiovasc Surg 1991; 102: 802
223. Durand D, Ader J-L, Rey J-P, et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int 1988; 34 Suppl 25: S196-7
224. Thürmann P, Harder S, Kirchmaier CM. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Eur J Clin Pharmacol 1945; 48: 241-7